Rallybio (NASDAQ:RLYB) Stock, Quote.Headers.trade-ideas

Rallybio

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AGEN

ALLR

ANET

APLD

BENF

CISS

CMAX

CPNG

DXYZ

EZGO

FRGE

GATO

GCTS

HRYU

HUBC

INTZ

LOVE

LXEH

LYEL

MGRM

MNDR

MOGU

MOTS

MRIN

NKLA

NRIX

NXPL

PXMD

RENT

RLYB

SAVA

SBFM

SERA

VERU

VIAO

Shares of  JPMorgan Chase &amp; Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.

Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Stock_Whisper_Index_Logo_6-copy

Biotech

Gaming

Restaurants

PUBM

RBLX

The weekly Benzinga Stock Whisper Index highlights five stocks that saw increased interest from readers. Here are this week&#39;s stocks to watch.

Benzinga&#39;s &#39;Stock Whisper&#39; Index: 5 Stocks Investors Secretly Monitor But Don&#39;t Talk About Yet

Pre-Market Outlook

DPRO

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

IONM

KZIA

ZPTA

Shares of  NextPlat Corp (NASDAQ: NXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year

Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket

Rallybio Corp

<ul>
<li>NVDA</li>
<li>WAY</li>
<li>LOT</li>
<li>QQQ</li>
<li>LUNR</li>
<li>MADE</li>
<li>GAP</li>
<li>DJT</li>
<li>META</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

LUNR

MADE

NVDA

Top 10 Trending Stocks On WallStreetBets As Of September 19, 2024 (Via Swaggy Stocks)

Barclays analyst Dan Levy initiates coverage on Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) with a Underweight rating and announces Price Target of $3.

Price Target

Initiation

Analyst Ratings

Barclays Initiates Coverage On Hertz Global Holdings with Underweight Rating, Announces Price Target of $3

WIIM

GLMD

Galmed Pharmaceuticals shares are trading higher after the company announced plans to broaden its drug development activities with two additional programs over the next two years.

RBC Capital analyst Luca Issi reiterates Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Sector Perform and maintains $8 price target.

Reiteration

EDIT

RBC Capital Reiterates Sector Perform on Editas Medicine, Maintains $8 Price Target

Barclays analyst Dan Levy initiates coverage on Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) with a Equal-Weight rating and announces Price Target of $105.

Barclays Initiates Coverage On Avis Budget Gr with Equal-Weight Rating, Announces Price Target of $105

On Wednesday, the Federal Trade Commission (FTC) said Ryan Cohen, managing partner of RC Ventures and Chairman and CEO of GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>), will pay a $985,320 civil penalty.
This <a target="_blank" href="https://www.ftc.gov/news-events/news/press-releases/2024/09/gamestop-ceo-ryan-cohen-pay-nearly-1-million-penalty-settle-antitrust-law-violation" rel="noreferrer noopener">fine</a> stems from charges that Cohen violated the Hart-Scott-Rodino (HSR) Act by failing to file the necessary paperwork during his acquisition of shares in Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>).
Cohen&#8217;s actions resulted in an acquisition that exceeded HSR filing thresholds, triggering the need for federal antitrust agencies to review the deal.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40816734/gamestop-analyst-says-retailer-could-close-all-stores-operate-as-bank-to-manage-los" rel="noreferrer noopener">GameStop Analyst Says Retailer Could Close All Stores, Operate As Bank To Manage Losses</a>.
According to the FTC&#8217;s complaint, Cohen&#8217;s purchase of more than 562,000 Wells Fargo voting securities required him to file an HSR form and wait for regulatory clearance before completing the transaction.
The HSR Act mandates that companies and individuals report large transactions to the FTC and the Department of Justice (DOJ) to allow for federal review.
As per the complaint, Cohen <a target="_blank" href="https://www.ftc.gov/system/files/ftc_gov/pdf/Cohen-Complaint-filed.pdf" rel="noreferrer noopener">acquired</a> 562,077 voting securities in Wells Fargo in March 2018, which resulted in his aggregated holdings of Wells Fargo securities exceeding the $100 million threshold, which in March 2018 was $168.8 million.
Cohen&#8217;s acquisition was not exempt under the Investment-Only Exemption of the HSR Act.
His emails and interactions with Wells Fargo&#8217;s leadership, where he advocated for a board seat and suggested business improvements, indicated an intent to influence the company&#8217;s operations. This intent disqualified his holdings from being considered passive investments.
In January 2021, Cohen made a corrective filing under the HSR Act for the March 2018 voting securities acquisition.
Under the law, finalizing a deal during the 30-day investigation period without approval is prohibited. At the time of Cohen&#8217;s violation, the maximum civil penalty for such infractions was $43,792 per day.
The FTC&#8217;s decision to settle the case and forward it to the DOJ for filing was unanimous, with a 5-0 vote.
Last week, GameStop reported second-quarter net sales of $798.0 million, down from $1.16 billion a year ago and missing the consensus of $895.7 million.
The video game retailer reported a profit of 1 cent per share, beating a Street consensus estimate of a loss <a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/40803991/gamestop-q2-earnings-highlights-revenue-miss-eps-beat-cash-update-and-more" rel="noreferrer noopener">of 9 cents per share</a>.
Price Action: GME stock is up 1.50% at $19.94 during the premarket session at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40927367/zimmer-biomet-to-stop-selling-cpt-hip-implant-system-by-end-of-2024-due-to-high-fracture-risks" target="_blank" rel="noreferrer noopener">Zimmer Biomet To Stop Selling CPT Hip Implant System By End Of 2024 Due To High Fracture Risks</a>.</li>
</ul>
Photo: Courtesy of Bill Jerome on Flickr

Large Cap

Legal

Management

General

GameStop CEO Ryan Cohen Penalized Nearly $1M Over Wells Fargo Share Acquisition

Wall Street analysts are increasing their expectations for further interest rate cuts following the Federal Open Market Committee&#8217;s decision to slash rates by a substantial <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">50 basis points on Wednesday. </a>
Even Fed Chair <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40927293/powell-defends-0-5-interest-rate-drop-as-right-thing-for-the-economy-doubles-down">Jerome Powell&#8216;s cautious remarks</a>, which initially rattled the markets, have not dampened the belief that the central bank is heading toward a more aggressive easing stance.
&#8220;The Fed attempted to sell its 50bp rate cut today as a &#8216;recalibration&#8217; of policy rates, rather than a sign of concern about the health of the labor market,&#8221; said Bank of America U.S. economist Aditya Bhave.
Bhave expects another 75 basis points of cuts in the fourth quarter and 125 basis points by 2025, bringing the neutral rate to a range of 2.75%-3%.
The S&amp;P 500 index, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), initially reached record highs after the rate cut decision but pulled back during Powell&#8217;s press conference.
The index is expected to open to all-time highs on Thursday amid a strong rally <a href="https://www.benzinga.com/premarket">during premarket trading. </a>
Positive labor market data released Thursday indicated that weekly jobless claims declined by 17,000 to 214,000 for the week ending Sept. 14, well below expectations of 230,000. Continuing jobless claims also fell more than expected to 1.83 million, down from 1.843 million and below the predicted 1.85 million.
<h3 class="wp-block-heading">US Stock Market To Hit New Record Highs After Election?</h3>
A bold market call came from veteran Wall Street investor Ed Yardeni, who now predicts the easing stance from the Federal Reserve will propel the stock market to climb to new all-time highs after the November presidential election.
&#8220;Fed Chair Jerome Powell reiterated that the Fed&#8217;s main focus now is to keep a lid on the unemployment rate,&#8221; said Yardeni.
&#8220;Now that the Fed is stimulating the economy, the hard-landing crowd should disperse,&#8221; he added. 
<h3 class="wp-block-heading">Goldman Sachs Expects Rate Cuts At Each Meeting</h3>
&#8220;The greater urgency suggested by today's 50bp cut and the acceleration in the pace of cuts that most participants projected for 2025 makes a longer series of consecutive cuts the most likely path,&#8221; said Goldman Sachs economist Jan Hatzius. 
Hatzius highlighted the significance of upcoming employment reports, indicating that the choice between a 25- and 50-basis-point cut in November could hinge on these data points.
The bond market is pricing in a 34-basis-point reduction for the next meeting, according to CME&#8216;s FedWatch tool. 
Goldman Sachs now projects a series of 25-basis-point cuts extending from November 2024 through June 2025, targeting a terminal rate of 3.25%-3.5%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40934972/wall-street-primed-for-relief-rally-as-traders-eye-jobless-claims-fedex-earnings-after-feds-50-basi">Wall Street Primed For Relief Rally As Traders Eye Jobless Claims, FedEx Earnings After Fed&#8217;s 50 Basis-Point Cut: Strategist Says These Stocks Will Gain Edge In First 6 Months Of Rate Cut</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

Wall Street Ramps Up Interest Rate Cut Bets After Fed Meeting: 'The Hard-Landing Crowd Should Disperse,' Economist Says

RBC Capital analyst Ken Herbert maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Outperform and raises the price target from $120 to $143.

FTAI

RBC Capital Maintains Outperform on FTAI Aviation, Raises Price Target to $143

JP Morgan analyst John Royall downgrades Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) from Neutral to Underweight and raises the price target from $300 to $337.

Downgrades

CASY

JP Morgan Downgrades Casey's General Stores to Underweight, Raises Price Target to $337

Signing Day Sports shares are trading higher after the company announced it will acquire sports gaming technology company Swifty Global.

JP Morgan analyst John Royall downgrades Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) from Neutral to Underweight and raises the price target from $415 to $435.

MUSA

JP Morgan Downgrades Murphy USA to Underweight, Raises Price Target to $435

Leerink Partners analyst Michael Cherny maintains Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) with a Market Perform and lowers the price target from $25 to $21.

PGNY

Leerink Partners Maintains Market Perform on Progyny, Lowers Price Target to $21

<a href="https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-announces-start-of-recruitment-in-2-new-phase-iii-trials-evaluating-saphnelo-in-cle-and-in-iim.html" title="https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-announces-start-of-recruitment-in-2-new-phase-iii-trials-evaluating-saphnelo-in-cle-and-in-iim.html">https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-announces-start-of-recruitment-in-2-new-phase-iii-trials-evaluating-saphnelo-in-cle-and-in-iim.html</a>

AstraZeneca Initiates Recruitment For Two New Phase III Trials Investigating SAPHNELO In Cutaneous Lupus Erythematosus (LAVENDER) And Idiopathic Inflammatory Myopathies (JASMINE)

The New Rack-Scale Ready FlexTwin&#x2122; Systems Deliver Unprecedented Compute-Density in a Multi-Node Form Factor, with DLC dual CPUs up to 500W Each per Node, Front Node Access and Optimized Networking&nbsp;
SAN JOSE, Calif., Sept. 19, 2024 /PRNewswire/ -- Supermicro, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) a Total IT Solution Provider for AI/ML, HPC, Cloud, Storage, and 5G/Edge is announcing the all-new FlexTwin family of systems which has been designed to address the needs of scientists, researchers, governments, and enterprises undertaking the world's most complex and demanding computing tasks. Featuring flexible support for the latest CPU, memory, storage, power and cooling technologies, FlexTwin is purpose-built to support demanding HPC workloads including financial services, scientific research, and complex modeling. These systems are cost-optimized for performance per dollar and can be customized to suit specific HPC applications and customer requirements thanks to Supermicro's modular Building Block Solutions&#xAE; design.

SMCI

Supermicro Announces The All-New FlexTwin Family Of Systems Which Has Been Designed To Address The Needs Of Scientists, Researchers, Governments, And Enterprises Undertaking The World's Most Complex And Demanding Computing Tasks

JP Morgan analyst Jessica Fye downgrades Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) from Overweight to Neutral and raises the price target from $52 to $57.

HALO

JP Morgan Downgrades Halozyme Therapeutics to Neutral, Raises Price Target to $57

RBC Capital analyst Gregory Renza reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and maintains $55 price target.

AGIO

RBC Capital Reiterates Outperform on Agios Pharmaceuticals, Maintains $55 Price Target

Semiconductor stocks especially the ones linked to artificial intelligence technology led by Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), Super Micro Computer, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) picked up after the U.S. Federal Reserve cut <a target="_blank" href="https://in.benzinga.com/markets/equities/24/09/40932103/it-stocks-on-the-rise-after-u-s-fed-cuts-interest-rate" rel="noreferrer noopener">benchmark interest rate</a> to spur growth.
The U.S. Federal Reserve decided to cut its benchmark interest rate by 50 basis points in a first since 2020, setting the interest rate at 4.75% and 5%. The cut is expected to boost discretionary spending by the companies.
The rate cut will be a welcome move, as semiconductor companies have invested heavily in Big Tech (including Microsoft Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>), Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Google parent Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)) spending on their artificial intelligence ambitions, which entail substantial capital expenditures.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40926422/super-micro-poised-for-expansion-as-gross-margin-concerns-ease-internal-control-risks-priced-in-anal" rel="noreferrer noopener">Super Micro Poised for Expansion as Gross Margin Concerns Ease, Internal Control Risks Priced In: Analyst</a>
The semiconductor companies are also under pressure due to the U.S. sanctions on China, a crucial market. Therefore, U.S. investors and the semiconductor chiefs closely watch the agenda of the next President, expecting a softer stance on China.
As per <a target="_blank" href="https://www.benzinga.com/news/24/09/40790177/harris-vs-trump-us-stocks-face-growing-risks-amid-economic-uncertainty-and-upcoming-presidential-ele" rel="noreferrer noopener">a CNBC survey</a>, Republican candidate Donald Trump appeared to be an investor favorite as the S&amp;P 500 and Nasdaq noted significant upside during Trump's tenure as President.
However, the current Biden administration has started doling out semiconductor grants to the companies to consolidate its position.
Contract chipmaker Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), a crucial AI chip supplier for U.S. semiconductor companies, remains hugely invested in <a target="_blank" href="https://www.benzinga.com/news/24/09/40928754/what-has-taiwan-semiconductor-stock-done-since-nvidia-earnings" rel="noreferrer noopener">its Arizona fab construction</a> to produce AI chips after bagging U.S. chip subsidies. It recently secured two smartphone chip deals from Google and Apple.
Price Actions: NVDA stock is up 3.16% at $116.95 premarket at last check Thursday. AMD is up 3.74% at $153.84, AVGO is up 3.45% at $167.25, SMCI is up 3.00% at $450.00, TSM is up 2.80% at $171.97, INTC is up 2.31% at $21.25, ARM is up 3.78% at $143.59.
Photo via Shutterstock

Government

Regulations

Tech

AMZN

AVGO

GOOG

GOOGL

INTC

MSFT

What's Going On With AI Related Stocks Nvidia, AMD, Broadcom And Super Micro On Thursday?

Zeta Marketing Platform brings next-generation AI capabilities to enhance Yahoo marketing and amplify precision and reach for brands
Zeta Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>), the AI-powered marketing Cloud, and Yahoo, a global media and tech company that serves as the trusted guide to the internet for hundreds of millions of people globally, today announced plans to migrate Yahoo's email marketing to the Zeta Marketing Platform (ZMP). Additionally, Zeta's Data Cloud is now interoperable with Yahoo ConnectID, enabling Yahoo DSP users to seamlessly activate audiences to deliver higher returns on investment.

ZETA

Zeta Global And Yahoo Announces Plans To Migrate Yahoo's Email Marketing To The Zeta Marketing Platform, Zeta's Data Cloud Is Now Interoperable With Yahoo ConnectID, Enabling Yahoo DSP Users To Seamlessly Activate Audiences To Deliver Higher Returns On Investment

GRYP

Gryphon Digital Mining Terminates Robby Chang As CEO And President, Appoints Steve Gutterman As New CEO Effective September 17, 2024

JP Morgan analyst Matthew Boss downgrades Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from Neutral to Underweight and raises the price target from $89 to $95.

FIVE

JP Morgan Downgrades Five Below to Underweight, Raises Price Target to $95

Rallybio (RLYB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Wolleben from JMP ...

Buy Rating Affirmed for Rallybio as RLYB212 Shows Blockbuster Potential in Underserved FNAIT Market

TD Cowen analyst Ritu Baral maintained a Buy rating on Rallybio (RLYB – Research Report) today. The company's shares closed yesterday at $1.45. Acc...

Rallybio (RLYB) Receives a Buy from TD Cowen

Rallybio (RLYB) has issued an update. Martin Mackay, Ph.D., has announced his intention to step down as Executive Chairman of Rallybio Corporation ...

Rallybio Executive Chairman Announces Plans to Step Down

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Rallybio (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlyb-stock-quote/">RLYB</a>) just reported results for the second quarter of 2024.<ul><li>Rallybio reported earnings per share of -37 cents. This was below the analyst estimate for EPS of -33 cents.</li><li>The company reported revenue of $299,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rlyb-stock-earnings-rallybio-for-q2-of-2024/">RLYB Stock Earnings: Rallybio Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RLYB Stock Earnings: Rallybio Misses EPS for Q2 2024

Rallybio's RLYB212 Shows Promise: Buy Rating Affirmed Amid Positive Trial and Market Potential

Ritu Baral, an analyst from TD Cowen, has initiated a new Buy rating on Rallybio (RLYB). Ritu Baral has given his Buy rating due to a combination o...

Buy Rating Justified by Rallybio's Financial Stability and Promising Clinical Trials

Rallybio GAAP EPS of -$0.67 misses by $0.30, revenue of $0.3M

Analyst Jonathan Wolleben from JMP Securities reiterated a Buy rating on Rallybio (RLYB – Research Report) and keeping the price target at $8.00. J...

Buy Rating on Rallybio: Promising RLYB212 Developments Signal Strong Market Potential

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Rallybio (RLYB – Research Report) today and set a price target of $6.00. Mitchel...

Buy Rating on Rallybio Stock Fueled by Promising RLYB212 Trial Outcomes and Potential FNAIT Treatment Breakthrough

Rallybio ( ($RLYB) ) has shared an update. Dr. Kush Parmar has announced his decision to step down from his positions as a board member and Chair o...

Dr. Kush Parmar Steps Down from Rallybio's Board and Committee

Press Releases

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Rallybio to Present at Upcoming Investor Conferences

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Rallybio

Rallybio (RLYB) Forecast

Rallybio (NASDAQ:RLYB) Stock, Quote.Headers.trade-ideas